Meeting
2023 ASCO Annual Meeting
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Authors
Lu Si
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
Lu Si , Zhengyun Zou , Weizhen Zhang , Meiyu Fang , Xiaoshi Zhang , Zhiguo Luo , Jing Chen , Gang Huang , Peng Zhang , Ying Cheng , Jiwei Liu , Jiyan Liu , Junping Zhang , Di Wu , Yu Chen , Xiaobiao Ma , Xiaoting Wei , Peng Sun , Zhongwei Jia , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05217303
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9510)
DOI
10.1200/JCO.2023.41.16_suppl.9510
Abstract #
9510
Poster Bd #
273
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2021 ASCO Annual Meeting
A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.
First Author: Yunpeng Yang
Poster
2020 ASCO Virtual Scientific Program
A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.
First Author: Lu Si
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben